7,751 Shares in Gilead Sciences, Inc. $GILD Bought by NBT Bank N.A.

NBT Bank N.A. bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,751 shares of the biopharmaceutical company’s stock, valued at approximately $1,155,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Gilead Sciences during the second quarter worth $15,393,785,000. State Street Corp grew its position in shares of Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after purchasing an additional 1,357,967 shares in the last quarter. Amundi grew its position in shares of Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $1,316,606,000. Finally, Deutsche Bank AG bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $918,387,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.7%

Gilead Sciences stock opened at $156.04 on Friday. The stock has a market cap of $193.48 billion, a P/E ratio of -58.44 and a beta of 0.31. Gilead Sciences, Inc. has a fifty-two week low of $114.02 and a fifty-two week high of $160.51. The firm’s fifty day moving average price is $149.10 and its 200-day moving average price is $137.85. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same quarter last year, the company earned $2.01 earnings per share. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.47 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were issued a $0.82 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the completion of the transaction, the chief executive officer owned 566,683 shares of the company’s stock, valued at approximately $83,812,415.70. The trade was a 2.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Royal Bank Of Canada increased their price objective on Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Barclays reduced their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Bank of America upped their price target on Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Zacks Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $159.81.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Inflammation pipeline expanded: Gilead agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash. The drug is intended for inflammatory bowel disease and could be developed alone or alongside Gilead’s emvistegrast, strengthening the company’s longer-term growth prospects. Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001
• Positive Sentiment: HIV development update: An ongoing study of a potential weekly oral HIV treatment adds another option to Gilead’s long-acting HIV portfolio. Positive clinical progress could support the company’s dominant HIV franchise and future revenue durability. Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower
• Positive Sentiment: Oncology collaboration: BioNTech and Gilead will test Gilead’s sacituzumab govitecan with BioNTech’s pumitamig in a global Phase 3 trial for advanced triple-negative breast cancer. The collaboration may improve the commercial potential of Gilead’s oncology platform, although clinical success remains uncertain. BioNTech, Gilead to Test Drug Combination
• Positive Sentiment: Favorable analyst and earnings expectations: TD Cowen reiterated a Buy view, while analysts indicated that Gilead could beat expectations in its upcoming quarterly report. Such forecasts support sentiment, though they are not guarantees of results. Gilead Sciences Receives a Buy from TD Cowen
• Neutral Sentiment: Gilead plans to present new data on rare liver diseases at The Liver Meeting 2026. The presentations could generate future catalysts, but no immediate clinical results were reported. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Legal overhang: Gilead will pay $45 million to settle Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines. The financial cost is modest relative to Gilead’s size, but the settlement adds regulatory and reputational risk. Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.